Work

P1.01-112 Phase 3, Randomized, Double-Blind Trial of First-Line Pembrolizumab With or Without Lenvatinib in Metastatic NSCLC: LEAP-007

Year: 2019

Type: article

Source: Journal of Thoracic Oncology

DOI: 10.1016/j.jtho.2019.08.827

Authors: T. Mekhail, S. Kim, K. Kubota, M. González Del Riego, L. Wu, A. Samkari, T.M. Fouad, J. Chih-Hsin Yang

Institutions: AdventHealth Orlando, Asan Medical Center, University of Ulsan, Nippon Medical School, Merck & Co., Inc., Rahway, NJ, USA (United States), Eisai (United States), National Taiwan University, National Taiwan University Hospital

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2982147621

FWCI: 0.185

Cites:

Cited by: 1

Related to: 10